Thank you Newman for the undeserved compliment. While I believe that my reasoning for the discrepancy between the planned number and final number of Control patients is probably correct, I am like many others, baffled by many events that have affected and are still affecting this trial.
However, I am optimistic that we will get many answers including a bases loaded TLD/publication homerun very soon.
Market Data 
Markets 
AI
